Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Breast cancer; Neuroendocrine tumours; Pancreatic cancer; Renal cell carcinoma
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 12 Jan 2016 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 04 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.